Management of the hypertensive patient with coronary artery disease

American Journal of Hypertension

Volumn 12, Issue 2 SUPPL. 1, 1999, Pages 56S-62S

  Oparil, Suzanne ^a,b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

Chronotherapy; Circadian rhythm; Coronary artery disease; Hypertension; Risk factors

Indexed keywords

AMLODIPINE; VERAPAMIL;

ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; CHRONOPHARMACOLOGY; CIRCADIAN RHYTHM; CLINICAL PROTOCOL; COMORBIDITY; CORONARY ARTERY DISEASE; DRUG BLOOD LEVEL; DRUG HALF LIFE; HUMAN; HYPERTENSION; PRIORITY JOURNAL; REVIEW;

CARDIOVASCULAR AGENTS; CHRONOTHERAPY; CIRCADIAN RHYTHM; CORONARY DISEASE; HEMODYNAMIC PROCESSES; HUMANS; HYPERTENSION; RISK FACTORS; SURVIVAL RATE;

EID: 0033044581     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-7061(98)00281-7     Document Type: Article

References (49)

1. World Health Organization Fact Sheet, 1996.
2. Burt VL, Whelton P, Roccella EJ, et al: Prevalence of hypertension in the US adult population: results from the third National Health and Nutrition Examination Survey, 1988-1991. Hypertension 1995;25:305-313.
3. Burt VL, Cutler JA, Higgins M, et al: Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population: data from the health examination surveys, 1990 to 1991. Hypertension 1995;26:60-69.
4. National Center for Health Statistics: Health, United States, 1996. Public Health Service, Hyattsville, MD, 1997.
5. Chartbook on Cardiovascular, Lung and Blood Disease. Morbidity and Mortality. National Institutes of Health, National Heart, Lung, and Blood Institute, Bethesda, MD, 1994.
6. National Heart, Lung, and Blood Institute: Fact Book Fiscal Year 1996. US Department of Health and Human Services. National Institutes of Health, Bethesda, MD, 1997.
7. U.S. Renal Data System: USRDS 1997 Annual Report. U.S. Department of Health and Human Services, National Institute of Diabetes and Digestive and Kidney Disease, Bethesda, MD, 1997.
8. Levy D, Larson MG, Vasan RS, et al: The progression from hypertension to congestive heart failure. JAMA 1996;275:1557-1562.
9. Luepker RV, McGovern PG, Sprafka JM, et al: Unfavorable trends in the detection and treatment of hypertension: the Minnesota Heart Survey (abst). Circulation 1995;91:938.
10. Meissner I, Whisnant JP, Sheps S, et al: Stroke prevention: assessment of risk in a community. The SPARC study, part I: blood pressure trends, treatment and control (abstract). Ann Neurol 1997;42:433.
11. Brown RD Jr, Whisnant JP, Sicks JD, et al: Stroke incidence, prevalence, and survival: secular trends in Rochester, Minnesota, through 1989. Stroke 1996;27:373-380.
12. Hall WD, Ferrario CM, Moore MA, et al: Hypertension-related morbidity and mortality in the southeastern United States. Am J Med Sci 1997;313:195-206.
13. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. NIH Publication No. 98-4080. National Institutes of Health, National Heart, Lung, and Blood Institute, National High Blood Pressure Education Program, Bethesda, MD, 1997.
14. Singh GK, Kochanek KD, MacDorman MF: Advance report of final mortality statitistics. 1994. Mon Vital Stat Rep 1996;45(suppl 3):1-76.
15. Klag MJ, Whelton PK, Randall BL, et al: End-stage renal disease in African-American and white men: 16-year MRFIT findings. JAMA 1997;277:1293-1298.
16. Hypertension Detection and Follow-up Program Cooperative Group: Five-year findings of the Hypertension Detection and Follow-up Program: mortality by race-sex and blood pressure level: a further analysis. J Community Health 1984;9:314-327.
17. Ooi WL, Budner NS, Cohen H, et al: Impact of race on treatment responses and cardiovascular disease among hypertensives. Hypertension 1989;14:227-234.
18. Kannel WB: Cardioprotection and antihypertensive therapy: the key importance of addressing the associated coronary risk factors (the Framingham experience). Am J Cardiol 1996;77:6B-11B.
19. Wilson PWF, Kannel WB: Hypertension, other risk factors and the risk of cardiovascular disease, in Laragh JH, Brenner BM (eds): Hypertension: Pathophysiology. Diagnosis and Management, 2nd ed. Raven Press, New York, 1995, p 99.
20. Kannel WB: Framingham study insights into hypertensive risk of cardiovascular disease. Hypertens Res 1995; 18:181-196.
21. Castelli WP, Anderson K, Wilson PW, Levy D. Lipids and risk of coronary heart disease. The Framingham Study. Ann Epidemiol 1992;2:23-28.
22. Austin MA: Epidemiologic association between hypertriglyceridemia and coronary heart disease. Semin Thromb Hemost 1988;14:137-142.
23. Gagnon DR, Zhang TJ, Brand FN, Kannel WB: Hematocrit and the risk of cardiovascular disease-the Framingham study: a 34-year follow-up. Am Heart J 1994; 127:674-682.
24. Pouliot MC, Despres JP, Lemieux S, et al: Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am J Cardiol 1994;73:460-468.
25. Willich SN, Linderer T, Wegscheider K, et al: Increased morning incidence of myocardial infarction in the ISAM Study: absence with prior beta-adrenergic blockade. Circulation 1989;80:853-858.
26. Toiler GH, Muller JE, Stone PH: Modifiers of timing and possible triggers of acute myocardial infarction in the Thrombolysis in Myocardial Infarction Phase II (TIMI II) Study Group. J Am Coll Cardiol 1992;20:1049-1065.
27. Muller JE, Ludmer PL, Willich SN, et al: Circadian variation in the frequency of sudden cardiac death. Circulation 1987;75:131-138.
28. Willich SN, Levy D, Rocco MB, et al: Circadian variation in the incidence of sudden cardiac death in the Framingham Heart Study population. Am J Cardiol 1987;60:801-806.
29. Rocco MB, Nabel EG, Selwyn AP: Circadian rhythms and coronary artery disease. Am J Cardiol 1987;59:13C-17C.
30. Mulcahy D, Cunningham D, Crean P, et al: Circadian variation of total ischaemic burden and its alteration with anti-anginal effects. Lancet 1988;ii:755-759.
31. Taylor CR, Hodge EM, White DA, and the Amlodipine Angina Study Group: Circadian rhythm of angina: similarity to circadian rhythms of myocardial infarction, ischemic ST segment depression, and sudden cardiac death. Am Heart J 1989;48:1098-1099.
32. Marler JR, Price TR, Clark GL, et al: Morning increase in onset of ischemic stroke. Stroke 1989;20:473-476.
33. Yasue H, Omote S, Takizawa A, et al: Circadian variation of exercise capacity in patients with Prinzmetal's variant angina: role of exercise-induced coronary arterial spasm. Circulation 1979;59:938-948.
34. Millar-Craig M, Bishop CN, Raftery EB: Circadian variation of blood pressure. Lancet 1978;i:795-797.
35. Turton MB, Deegan T: Circadian variations of plasma catecholamine, cortisol and immunoreactive insulin concentrations in supine subjects. Clin Chim Acta 1974; 55:388-397.
36. Gordon RD, Wolfe LK, Island DP, Liddle GW: A diurnal rhythm in plasma renin activity in man. J Clin Invest 1966;45:1587-1592.
37. Weitzman ED, Fukushima D, Norgeiro C, et al: Twenty-four hour pattern of the episodic secretion of cortisol in normal subjects. J Clin Endocrinol Metab 1971;33:14-22.
38. Mulcahy D: Timing of cardiovascular events and importance of intelligent prescribing. Blood Press Monit 1996;1(suppl 1):S13-S16.
39. Quyyumi AA, Panza JA, Diodati JG, et al: Circadian variation in ischemic threshold: a mechanism underlying the circadian variation in ischemic events. Circulation 1992;88:22-28.
40. Tofler GH, Brezinski D, Schafer AI, et al: Concurrent morning increase in platelet aggregability and the risk of myocardial infarction and sudden cardiac death. N Engl J Med 1987;316:1514-1518.
41. Fujita M, Franklin D: Diurnal changes in coronary blood flow in conscious dogs. Circulation 1987;76:488-491.
42. Brezinski DA, Tofler GH, Muller JE, et al: Morning increase in platelet aggregability: association with assumption of the upright position. Circulation 1988;78: 35-40.
43. Andreotti F, Davies GJ, Hackett DR, et al. Major circadian variations in fibrinolytic factors and possible relevance to time of onset of myocardial infarction, sudden cardiac death and stroke. Am J Cardiol 1988;62: 635-637.
44. Psaty BM, Smith NL, Siscovick DS, et al: Health outcomes associated with antihypertensive therapies used as first-line agents: a systematic review and meta-analysis. JAMA 1997;277:739-745.
45. Moser M, Hebert PR: Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials. J Am Coll Cardiol 1996;27:1214-1218.
46. MacMahon S, Rodgers A: The effects of blood pressure reduction in older patients: an overview of five randomized controlled trials in elderly hypertensives. Clin Exp Hypertens 1993;15:967-978.
47. Palatini P: Can an angiotensin-converting enzyme inhibitor with a short half-life effectively lower blood pressure for 24 hours? Am Heart J 1992;123:1421-1425.
48. Frishman WH, Glasser SP, Stone PH, et al: Comparison of controlled-onset, extended release verapamil to amlodipine and amlodipine plus atenolol on exercise performance in ambulatory ischemia in patients with chronic stable angina pectoris. Am J Cardiol (in press).
49. Gupta SK, Yih BM, Atkinson L, Longstreth J: The effect of food, time of dosing, and body position on the pharmacokinetics and pharmacodynamics of verapamil and norverapamil. J Clin Pharmacol 1995; 35:1083-1093.